Evidence map›Paper›PMID 31134085›Full record

ReviewFrontiers in immunology2019

Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1.

George K Lewis, Margaret E Ackerman, Gabriella Scarlatti, Christiane Moog, Marjorie Robert-Guroff, Stephen J Kent, Julie Overbaugh, R Keith Reeves, Guido Ferrari, Bargavi Thyagarajan

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. A Single-Dose Bundibugyo Virus Vaccine Protects Macaques Within 3 Days.bioRxiv : the preprint server for biology · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 4 countries.

George K LewisDivision of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.
Margaret E AckermanThayer School of Engineering, Dartmouth College, Hanover, NH, United States.
Gabriella ScarlattiViral Evolution and Transmission Unit, Department of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Christiane MoogINSERM U1109, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.
Marjorie Robert-GuroffVaccine Branch, Center for Cancer Research, National Cancer Institute, National Institues of Health, Bethesda, MD, United States.
Stephen J KentDepartment of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Julie OverbaughDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
R Keith ReevesCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, United States.
Guido FerrariDepartment of Surgery and Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, United States.
Bargavi ThyagarajanGlobal HIV Vaccine Enterprise, New York, NY, United States.
Beth Israel Deaconess Medical Center · USCenter for Cancer Research · USDartmouth College · USDuke Medical Center · USFred Hutch Cancer Center · USGlobal HIV Vaccine Enterprise · USInserm · FRPeter Doherty Institute · AUUniversity of Maryland, Baltimore · USVita-Salute San Raffaele University · IT

Funding

Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI GEORGIA Doris TOMARAS · 2005 to 2026
$50.5M
Development of a Vaccine for HIVAIDS: Humoral ImmunityZIABC011058 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROBERT-GUROFF, MARJORIE · 2009 to 2020
$23.3M
Physical Resources CoreP01AI120756 · NIAID · DUKE UNIVERSITY · PI TOMARAS, GEORGIA DORIS · 2016 to 2020
$17.1M
Project 3- Mucosal Determinants of Virus TransmissionP01AI124912 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI GALLO, ROBERT C · 2016 to 2019
$14.4M
Directing Antibody Effector Activity via Controlled IgG Subclass SwitchingR01AI131975 · NIAID · DARTMOUTH COLLEGE · PI ACKERMAN, MARGARET E · 2017 to 2020
$2.6M
NIAID NIH HHS P01 AI120756NIAID NIH HHS P01 AI124912NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI131975
6 · The paper itself

Abstract

It is now well-accepted that Fc-mediated effector functions, including antibody-dependent cellular cytotoxicity (ADCC), can contribute to vaccine-elicited protection as well as post-infection control of HIV viremia. This picture was derived using a wide array of ADCC assays, no two of which are strictly comparable, and none of which is qualified at the clinical laboratory level. An earlier comparative study of assay protocols showed that while data from different ADCC assay formats were often correlated, they remained distinct in terms of target cells and the epitopes and antigen(s) available for recognition by antibodies, the effector cells, and the readout of cytotoxicity. This initial study warrants expanded analyses of the relationships among all current assay formats to determine where they detect overlapping activities and where they do not. Here we summarize knowns and unknowns of assaying ADCC against HIV-1.

Indexed as

Antibodies, NeutralizingAntibody-Dependent Cell CytotoxicityHIV-1HIV AntibodiesHIV InfectionsHIV SeropositivityHumansImmunoglobulin Fc FragmentsKiller Cells, NaturalMacrophagesNeutrophilsAntibodies, NeutralizingHIV AntibodiesImmunoglobulin Fc FragmentsADCC—antibody dependent cellular cytotoxicityantibodieseffector functionFc receptorHIV—human immunodeficiency virus

Identifiers

PMID31134085
PMCPMC6522882
OpenAlexW2944123341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.